Cost-effectiveness Analysis of Selpercatinib Versus Chemotherapy and Pembrolizumab in the First-Line Treatment of Rearranged During Transfection Fusion–positive Non-Small Cell Lung Cancer in the United States
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY（2024）
关键词
Cost,Effectiveness,Non small cell lung cancer,Rearranged during transfection,Selpercatinib
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要